What drove Health Care this quarter
S&P 500 · Health Care sector · updated August 10, 2026 · rolling 90-day window
The Health Care sector exhibited robust performance in the second quarter of 2026, with 72% of companies beating earnings expectations. Key themes driving this quarter included strong demand for innovative treatments, strategic acquisitions, and disciplined cost management. Companies like Elevance Health and Eli Lilly highlighted the growing demand in Medicare Advantage and obesity treatments, respectively, with Elevance raising its EPS guidance due to solid execution in managing healthcare costs. Eli Lilly's revenue growth of $8.5 billion was underpinned by promising data from its obesity treatment pipeline, particularly retatrutide, prompting a raised full-year revenue outlook. In contrast, Johnson & Johnson missed expectations despite strong operational growth due to challenges in its MedTech segment, which investors should monitor closely. Strategic acquisitions also played a pivotal role, as Vertex Pharmaceuticals announced the acquisition of Crinetics Pharmaceuticals, aimed at diversifying its portfolio and enhancing revenue growth. Moderna and Gilead Sciences showcased successful product launches and pipeline advancements, reinforcing the sector's focus on innovation and growth potential. However, companies like Baxter International and Align Technology faced challenges, with Baxter reporting flat growth amid restructuring efforts and Align navigating a sluggish North American market. Overall, the sector's positive momentum is supported by a strong pipeline of innovative therapies and strategic initiatives, although regulatory pressures and competitive dynamics remain critical risks to watch.
Health Care companies this quarter
The individual earnings calls behind this synthesis. Each links to the company's full transcript archive — free to read.
In the second quarter of 2026, Elevance Health reported adjusted diluted earnings per share (EPS) of $7.45, exceeding expectations and prompting management to raise full-year EPS guidance to at least $27. Revenue for the quarter was $49.8 b…
In the second quarter of 2026, Johnson & Johnson (JNJ:US) reported strong financial results, with worldwide sales of $25.3 billion, reflecting a 5.6% operational growth. The company also achieved net earnings of $5.5 billion, with diluted E…
In the second quarter of fiscal year 2026, Biogen Inc. reported significant advancements in its Alzheimer's treatment pipeline, particularly with diranersen, which has shown promising results in reducing tau tangles and improving cognitive
In the second quarter of 2026, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion, which is expected to enhance Vertex's revenue growth and diversify its portfolio. The…
In the second quarter of fiscal year 2026, Moderna, Inc. reported revenues of $3.5 billion, which exceeded analyst expectations of $3.2 billion, reflecting a 15% year-over-year increase. The company also reported earnings per share (EPS) of…
In the June 25, 2026 earnings call, Merck announced its definitive agreement to acquire Bio-Techne Corporation for USD 73 per share, marking a significant strategic move in the Life Science sector. The acquisition is expected to be immediat…
In the second quarter of fiscal year 2026, Vertex Pharmaceuticals (VRTX) reported strong performance driven by its cystic fibrosis (CF) franchise and the launch of JOURNAVX in the pain market. The company generated $1.2 billion in revenue,
In the Goldman Sachs Healthcare Conference on June 10, 2026, Elevance Health, Inc. provided a positive outlook for its Medicare Advantage (MA) segment, indicating no material impact from recent CMS sanctions. The company reaffirmed its guid…
In the second quarter of fiscal year 2026, Eli Lilly and Company reported robust performance driven by its expanding obesity treatment portfolio, particularly the promising data from its investigational drug retatrutide. The company achieve…
In the second quarter of 2026, Moderna, Inc. (MRNA) reported revenues of $2 billion, reflecting a year-over-year growth of 10%, in line with management's guidance. The company is optimistic about future growth driven by its expanding produc…
In the second quarter of fiscal year 2026, Bristol-Myers Squibb (BMY) reported revenues of $12.5 billion, exceeding expectations of $11.9 billion, reflecting a robust 10% year-over-year growth. Earnings per share (EPS) came in at $2.30, bea…
In the second quarter of fiscal year 2026, Gilead Sciences, Inc. reported a revenue of $5.2 billion, exceeding the consensus estimate of $4.9 billion, marking a 12% increase year-over-year. Earnings per share (EPS) came in at $1.45, beating…
In the second quarter of fiscal year 2026, Merck & Co., Inc. reported strong progress across its portfolio, with management expressing confidence in achieving over 50% of their $70 billion commercial target ahead of schedule. Revenue for th…
In Q1 2026, Baxter International Inc. reported revenues of $3.5 billion, which is in line with expectations, but the company faces challenges with flat growth and a focus on stabilizing operations. The management indicated a cautious outloo…
In the second quarter of fiscal year 2026, AbbVie Inc. reported strong financial results, with revenues of $14.5 billion, exceeding expectations by $500 million, and earnings per share (EPS) of $2.50, beating estimates by $0.15. Management
In the Q1 2026 earnings call, Johnson & Johnson (JNJ:US) reported revenue of $15.4 billion, reflecting a 7% year-over-year growth, with U.S. growth at approximately 10%. Management emphasized that they are on track for a compound annual gro…
In the first quarter of fiscal year 2026, Amgen Inc. (AMGN:US) reported a revenue increase of 6% year-over-year, reaching $6.5 billion, and non-GAAP earnings per share (EPS) rose 5% to $3.10. Management highlighted strong performance from k…
Incyte Corporation's Q2 2026 earnings call highlighted a significant transition from reliance on Jakafi to a broader portfolio of growth drivers, with the core business expected to generate approximately $1.7 billion this year, up over 30%
In the first quarter of fiscal year 2026, Revvity, Inc. reported solid revenue growth driven by its Diagnostics and Life Sciences segments. Revenue reached $1.2 billion, reflecting a 6% increase year-over-year, while earnings per share (EPS…
In the second quarter of 2026, Universal Health Services, Inc. (UHS) reported revenue of $3.2 billion, reflecting a 5% increase year-over-year, while earnings per share (EPS) came in at $1.85, above the consensus estimate of $1.75. Manageme…
In the second quarter of fiscal year 2026, Regeneron Pharmaceuticals reported strong revenue growth driven by its core franchises, particularly Dupixent and EYLEA. The company achieved revenue of $3.2 billion, exceeding expectations of $3.1…
In the second quarter of fiscal year 2026, Insulet Corporation (PODD) reported strong performance despite facing challenges from recent product recalls. The company highlighted a significant expansion in its sales force and the successful l…
In the second quarter of 2026, Zimmer Biomet Holdings, Inc. reported revenues of $8.5 billion, which aligns with expectations but reflects a challenging transition year as the company restructures its sales force. The company guided for a m…
Align Technology, Inc. (ALGN:US) reported a challenging quarter with a revenue guidance of 1% sequential growth for Q2 2026, significantly lower than historical trends of 2-3%. The company highlighted a sluggish North American retail market…
In the Q1 2026 earnings call, Pfizer Inc. (PFE:US) reported strong performance despite a significant decline in COVID-related revenues. The company achieved revenues of $16.5 billion, surpassing expectations of $15.0 billion, and delivered
In the June 6, 2026 earnings call, Pfizer Inc. (PFE:US) focused on its investigational obesity treatment, berobenatide, which is positioned as a potential first-in-class monthly GLP-1 receptor agonist. The management highlighted promising P…
In the second quarter of fiscal year 2026, The Cooper Companies reported record revenue of $1.08 billion, an 8% increase year-over-year, and non-GAAP earnings per share of $1.21, up 26%. The company has maintained its full-year revenue guid…
In the Q2 2026 earnings call, Merck & Co. reported strong performance driven by advancements in its oncology portfolio, particularly with KEYTRUDA and the promising data from recent ASCO presentations. Revenue for the quarter reached $15.2
In the first quarter of fiscal year 2026, Amgen Inc. (AMGN:US) reported revenue of $6.5 billion, representing a 6% increase year-over-year, and non-GAAP earnings per share of $3.45, up 5% YoY. Management highlighted the strong performance o…
In the second quarter of fiscal year 2026, Align Technology, Inc. (ALGN:US) reported a revenue growth of 3% to 4%, consistent with prior guidance, while maintaining an operating margin improvement of 100 basis points. The company emphasized…
In Veeva Systems' Fiscal 2027 First Quarter results for the period ending April 30, 2026, the company reported total revenue of $883 million and non-GAAP operating income of $395 million, both exceeding prior guidance. Management highlighte…
In the first quarter of 2026, Insulet Corporation (PODD:US) reported approximately $2.7 billion in global revenue, reflecting a 30% year-over-year growth in constant currency. The company also achieved nearly 40% growth in adjusted earnings…
In the second quarter of fiscal year 2026, Pfizer Inc. reported revenues of $14.2 billion, exceeding expectations of $13.5 billion, marking a 10% year-over-year increase. Earnings per share (EPS) came in at $2.50, beating estimates by $0.15…
In the first quarter of fiscal 2026, Labcorp Holdings Inc. (LH:US) reported a revenue increase of 6% and an adjusted EPS growth of 11%, prompting management to raise full-year guidance for both metrics. The company now expects revenue growt…
In the second quarter of fiscal year 2026, Waters Corporation (WAT:US) reported strong financial results, with revenue surpassing guidance by approximately $60 million and achieving double-digit growth in its legacy business. The company po…
In the second quarter of fiscal 2026, Align Technology, Inc. (ALGN:US) reported revenues of $1.05 billion, exceeding expectations of $1.02 billion, marking a 12% year-over-year increase. Earnings per share (EPS) were $1.75, beating the cons…
In the Q1 2026 earnings call for Charles River Laboratories International, Inc. (CRL:US), management highlighted a strategic shift towards improved margins and growth through divestitures and acquisitions. Revenue for the quarter was not ex…
In the second quarter of fiscal year 2026, Solventum Corporation (SOLV:US) reported a strong performance with revenue growth driven by strategic initiatives and a robust product pipeline. The company achieved revenue of $1.4 billion, exceed…
In the first quarter of 2026, IQVIA Holdings Inc. reported strong financial results, with revenue and earnings exceeding expectations. The company achieved revenue growth of 6%, with organic growth of 3%, and EPS guidance for the fiscal yea…
Agilent Technologies reported a strong Q2 2026, achieving revenue growth of 6.3% year-over-year and 14% EPS growth, exceeding management's guidance. The company experienced broad growth across its segments, particularly in diagnostics and s…
In the first quarter of fiscal year 2026, GE HealthCare Technologies Inc. reported a revenue of $4.2 billion, reflecting a 2.9% year-over-year growth, which was slightly above the guided range of 2% to 3%. However, the company adjusted its
In the fourth quarter of fiscal 2026, Medtronic plc reported revenue of $9.8 billion, reflecting a 9.9% increase year-over-year, and adjusted EPS of $1.55, exceeding expectations. For the full fiscal year, revenue reached $36.4 billion, up
In the Q4 FY2026 earnings call, ResMed Inc. reported strong financial performance with revenues of $1.2 billion, exceeding expectations and reflecting a year-over-year growth of 10%. Earnings per share (EPS) came in at $0.85, beating consen…
In the second quarter of fiscal year 2026, West Pharmaceutical Services, Inc. reported strong performance driven by its high-value product (HVP) components, which grew 18% year-over-year. Revenue guidance for the full year was maintained at…
In the first quarter of 2026, Zoetis Inc. reported revenues of $2.4 billion, which was in line with expectations but reflected a 1% year-over-year decline. The company faced headwinds from a challenging macroeconomic environment and increas…
In the Q1 2026 earnings call for Charles River Laboratories International, Inc. (CRL:US), management reported a revenue of $995.8 million, reflecting a 1.5% decline year-over-year, which was in line with expectations. Non-GAAP EPS was $2.06…
In the Q2 2026 earnings call, Moderna, Inc. (MRNA) highlighted significant advancements in its oncology pipeline, particularly the promising results from the Phase II KEYNOTE-942 study of Intismeran, an individualized neoantigen therapy. Th…
In the second quarter of fiscal year 2026, Merck & Co., Inc. (MRK:US) reported total revenue of $15.2 billion, exceeding analyst expectations of $14.5 billion, representing a 10% year-over-year increase. Earnings per share (EPS) came in at
In the Q1 2026 earnings call for Vertex Pharmaceuticals (VRTX), management reported a revenue of $1.2 billion, which was in line with expectations, and an EPS of $0.85, beating estimates by $0.05. The company maintained its full-year guidan…
In the first quarter of 2026, Zoetis Inc. reported a revenue of $1.5 billion, reflecting a 4% decline year-over-year, which was below analyst expectations. The company has updated its full-year guidance for organic operational growth to a r…
In the Q1 2026 earnings call, Eli Lilly and Company (LLY:US) reported revenues of $8.5 billion, exceeding expectations of $8.1 billion, marking a 12% year-over-year increase. Earnings per share (EPS) were $2.45, beating estimates by $0.15.
In the Q1 2026 earnings call for Gilead Sciences, management highlighted a strong operational position, with a robust pipeline and ongoing diversification efforts. Revenue for the quarter reached $7.5 billion, slightly above the $7.3 billio…
AbbVie Inc. (ABBV:US) did not hold an earnings call on May 28, 2026, as the provided transcript pertains to a webinar on EU clinical trial regulations rather than a financial earnings report. Therefore, there are no updates on revenue, earn…
In the Q1 2026 earnings call, Moderna, Inc. reported a revenue of $1.9 billion, a significant decline from $18 billion in 2022, but management signaled a stabilization and potential growth trajectory moving forward. CEO Stéphane Bancel emph…
In the Q2 2026 earnings call, Align Technology, Inc. (ALGN:US) reported a revenue of $850 million, reflecting a 1% increase year-over-year, which was below expectations. The company maintained a cautious outlook, guiding for Q2 revenue grow…
In Q2 2026, Agilent Technologies reported revenue of $1.83 billion, representing a 6.3% core growth year-over-year, exceeding guidance by 80 basis points. Earnings per share (EPS) reached $1.49, up 14% year-over-year, also surpassing the to…
In the first quarter of fiscal year 2026, Henry Schein, Inc. reported solid performance with revenue growth driven by a healthy dental market and improved sales momentum. The company achieved revenue of $3.5 billion, which was slightly abov…
In the Q2 2026 earnings call, Johnson & Johnson (JNJ:US) reported a strong performance, with management projecting a 6.1% adjusted operational growth for the full year, leading to a revenue milestone of over $100 billion. The company exceed…
In the first quarter of fiscal year 2026, IDEXX Laboratories reported strong performance with revenue of $1.1 billion, exceeding expectations and reflecting a 10% year-over-year increase. Earnings per share (EPS) came in at $1.25, beating e…
In the Q2 2026 earnings call, Boston Scientific Corporation (BSX:US) reported a revenue guidance reduction to 6% for the fiscal year, down from previous expectations. The company anticipates organic growth of 5% to 7% for Q2, with managemen…
In the first quarter of 2026, HCA Healthcare reported revenue of $14.2 billion, reflecting a 5% year-over-year increase, while adjusted EBITDA was impacted by a $150 million headwind due to a decline in exchange volume. Management reaffirme…
In the Q1 2026 earnings call for Universal Health Services, Inc. (UHS), management reported strong performance with revenue of $3.2 billion, representing a 10% increase year-over-year, and earnings per share (EPS) of $1.85, beating analyst
In the first quarter of fiscal year 2026, Thermo Fisher Scientific Inc. (TMO:US) reported revenues of $11.5 billion, reflecting a 5% year-over-year increase, and adjusted earnings per share (EPS) of $3.15, exceeding expectations by $0.10. M…
In the first quarter of fiscal year 2026, Vertex Pharmaceuticals reported revenues of $12.95 billion to $13.1 billion, driven by strong growth in its cystic fibrosis (CF) franchise and new product launches. The company expects to generate a…
In the Q1 2026 earnings call, Johnson & Johnson (JNJ) reported strong growth in its electrophysiology (EP) segment, with the global market now valued at $16 billion and growing at 12-13%. Management highlighted a significant opportunity in
In the Q1 2026 earnings call, Gilead Sciences, Inc. reported a revenue of $7.2 billion, exceeding the consensus estimate of $6.9 billion, reflecting a 10% year-over-year growth. Earnings per share (EPS) came in at $1.50, beating expectation…
Incyte Corporation reported its Q1 2026 earnings on May 19, 2026, revealing a revenue of $300 million, which was in line with expectations. The company maintained its full-year guidance of $1.2 billion in revenue. Notably, management highli…
In the Q1 2026 earnings call, Moderna, Inc. reported revenues of $1.9 billion, exceeding expectations and establishing a strong foundation for future growth. The company achieved significant cost reductions, cutting $2 billion in cash costs…
In the first quarter of fiscal year 2026, DexCom, Inc. (DXCM:US) reported revenue of $4.6 billion, consistent with expectations, and maintained its guidance for double-digit growth through 2030. The company emphasized its commitment to expa…
In the Q1 2026 earnings call, Bristol-Myers Squibb (BMY:US) reported a 12% year-over-year growth in its growth portfolio, driven by strong performances from CAMZYOS and REBLOZYL, which are annualizing at over $1 billion and north of $2 bill…
In Q1 2026, Henry Schein, Inc. reported strong growth in its dental and technology segments, while experiencing softness in the medical sector due to a weak flu season. Revenue growth was driven by dynamic pricing and market share gains, wi…
In the first quarter of fiscal year 2026, Stryker Corporation reported a revenue of $4.5 billion, which was in line with expectations but reflects a significant recovery from a cyber incident that impacted operations earlier in the year. Th…
Incyte Corporation reported strong performance in Q1 2026, with revenue growth driven primarily by Jakafi and Opzelura. The company achieved a revenue increase of 7% year-over-year, with Jakafi sales contributing significantly due to broad-…
In the Q1 2026 earnings call, Biogen Inc. (BIIB:US) showcased a strategic pivot towards immunology, particularly in multiple sclerosis (MS) and lupus, which could significantly impact future revenue streams. The company reported revenues of…
In the first quarter of fiscal year 2026, Danaher Corporation reported solid operational performance, achieving a revenue of $6.5 billion, which was slightly above expectations. The company experienced a 50 basis points operational core gro…
In the first quarter of fiscal 2026, Baxter International Inc. reported a revenue of $3.1 billion, exceeding expectations of $2.9 billion, marking a 5% year-over-year increase. Earnings per share (EPS) were $0.75, beating the consensus esti…
In the Q1 2026 earnings call, AbbVie Inc. (ABBV:US) reported revenue of $15.2 billion and earnings per share (EPS) of $2.80, both exceeding consensus estimates. Management expressed confidence in exceeding consensus revenue growth projectio…
In the first quarter of fiscal year 2026, IQVIA Holdings Inc. reported revenue and EPS that exceeded the high end of expectations, signaling strong operational performance. Revenue growth was particularly robust in Commercial Solutions and
In the first quarter of 2026, Amgen Inc. (AMGN:US) reported a revenue increase of 6% year-over-year, reaching $6.5 billion, and a non-GAAP EPS growth of 5%, amounting to $4.25. The company highlighted strong performance from its six key gro…
In Q1 2026, Solventum Corporation (SOLV:US) reported strong performance driven by its Health Information Systems (HIS) segment, which is seeing accelerated growth. Revenue for the quarter was approximately $100 million, with management high…
In the first quarter of fiscal year 2026, Revvity, Inc. reported a solid performance with revenue growth of 3% and adjusted EPS of $0.50, slightly below the previous year's $0.55 due to the divestiture of its immunodiagnostics business in C…
In the first quarter of fiscal year 2026, Insulet Corporation reported strong revenue growth of 28% in the U.S., although guidance for Q2 was slightly below expectations at 18% to 20%. The company raised its full-year revenue growth guidanc…
In the first quarter of fiscal year 2026, The Cigna Group reported a revenue of $45.2 billion and an EPS of $3.10, both exceeding market expectations. The company is transitioning its pharmacy benefit management (PBM) model to a rebate-free…
In the third quarter of fiscal 2026, Cardinal Health, Inc. reported strong financial results, with revenue growth driven by robust demand across its pharmaceutical and specialty businesses. The company achieved an 11% revenue increase, alon…
In the first quarter of 2026, Zimmer Biomet Holdings, Inc. (ZBH:US) reported a revenue growth of 3%, hitting the top end of their guidance range of 1% to 3%. The company generated earnings that exceeded expectations, although specific figur…
In the first quarter of 2026, Mettler-Toledo International Inc. (MTD) reported revenue growth of 3% and earnings growth of 9%, which was in line with expectations but included a higher-than-expected contribution from M&A. Management acknowl…
In the second quarter of fiscal year 2026, Cencora, Inc. reported a revenue of $3.2 billion, reflecting a 6% year-over-year growth, which was below the expected 7% growth. The company maintained its full-year EPS guidance of $17.65 to $17.9…
Cencora, Inc. reported its second quarter earnings for fiscal year 2026, highlighting a revenue of $2.1 billion and EPS guidance of $17.65 to $17.90. The company expressed confidence in its full-year guidance despite a slight decline in org…
In the first quarter of fiscal year 2026, Elevance Health, Inc. reported operating revenue of $197.6 billion, marking a 13% increase year-over-year. The company achieved an operating gain of $7.2 billion, with $4.1 billion returned to share…
In the first quarter of fiscal year 2026, Edwards Lifesciences Corporation (EW:US) reported strong performance, with revenue growth driven primarily by TAVR procedures. The company increased its full-year revenue guidance to a range of 9% t…
In the first quarter of fiscal year 2026, DaVita Inc. reported a revenue of $3.1 billion, which was in line with expectations, and an earnings per share (EPS) of $1.10, beating estimates by $0.05. Management raised treatment volume guidance…
In the first quarter of 2026, Gilead Sciences, Inc. (GILD) reported strong performance, driven by its HIV franchise and recent acquisitions. Revenue reached $6.5 billion, exceeding analyst expectations of $6.2 billion, with earnings per sha…
In Q1 2026, West Pharmaceutical Services, Inc. (WST:US) reported a strong performance with revenue growth driven by high demand in HVP non-GLP-1 components, achieving double-digit growth. The company experienced a positive surprise in earni…
In the first quarter of fiscal year 2026, Universal Health Services, Inc. (UHS) reported revenues of $3.2 billion, a slight increase from the previous year, but fell short of analyst expectations. Earnings per share (EPS) were $1.45, missin…
In the Q1 2026 earnings call for Moderna, Inc. (MRNA:US), management guided for up to 10% revenue growth, driven by increased sales from MNXpike and strategic partnerships in the U.K., Canada, and Australia. The company reported cash cost r…
In the Q1 2026 earnings call, Johnson & Johnson (JNJ:US) reported strong momentum in its pharmaceutical division, particularly in oncology and immunology, which could positively influence stock performance. The company highlighted a signifi…
In the first quarter of fiscal year 2026, GE HealthCare Technologies Inc. (GEHC:US) reported revenue of $4.5 billion, slightly below expectations, leading to a reduction in full-year guidance. The company cited significant inflationary pres…
In the earnings call for Q1 2026, Regeneron Pharmaceuticals reported strong performance driven by its flagship product, DUPIXENT, which is on a run rate of approximately $20 billion annually. The company announced a commitment of $27 billio…
In the third quarter of fiscal 2026, Bio-Techne Corporation reported a revenue decline of 2%, contrasting with a 6% growth in the prior year. The company attributed this downturn to a timing issue with a significant order and a slowdown in
In the fourth quarter of fiscal 2026, McKesson Corporation reported strong financial performance, with revenue growth and adjusted operating profit growth exceeding long-range targets. The company achieved an 18% increase in adjusted EPS an…
In the Q2 2026 earnings call for Becton, Dickinson and Company (BDX), management reported revenue of $4.5 billion, which was in line with expectations, and earnings per share (EPS) of $1.25, slightly missing the consensus estimate of $1.30.…
In the first quarter of fiscal year 2026, Viatris Inc. (VTRS) reported a revenue of $4.5 billion, reflecting a 2% operational growth driven by a strong portfolio, particularly in North America. Earnings per share (EPS) came in at $0.55, con…
In the fourth quarter of fiscal 2026, STERIS plc reported total revenue growth of 7%, with adjusted earnings per share increasing 3% to $2.83. The company maintained its guidance for fiscal 2027, projecting revenue growth of 7% to 8% and ad…